STERIS (STE) 10-Q 7 Feb 25 2025 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	9 Months Ended
	Dec. 31, 2024	Feb. 04, 2025
Entity Information [Line Items]
Entity Registrant Name	STERIS plc
Entity Central Index Key	0001757898
Document Type	10-Q
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Amendment Flag	false
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--03-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		98,250,789
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-38848
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1455064
Local Phone Number	1 232 2000
City Area Code	353
Document Quarterly Report	true
Entity Address, Address Line One	70 Sir John Rogerson's Quay,
Entity Address, City or Town	Dublin 2,
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 R296
Entity Shell Company	false
STE Two700 Senior Notes Due2031 Member
Entity Information [Line Items]
Title of 12(b) Security	2.700% Senior Notes due 2031
Trading Symbol	STE/31
Security Exchange Name	NYSE
Two700 Senior Notes Due2051 Member
Entity Information [Line Items]
Title of 12(b) Security	3.750% Senior Notes due 2051
Trading Symbol	STE/51
Security Exchange Name	NYSE
Ordinary Shares
Entity Information [Line Items]
Title of 12(b) Security	Ordinary Shares, $0.001 par value
Trading Symbol	STE
Security Exchange Name	NYSE

CONSOLIDATED BALANCE SHEETS (un

CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Current assets:
Cash and cash equivalents	$ 155,178	$ 207,020
Accounts receivable (net of allowances of $22,359 and $22,984, respectively)	915,199	1,008,315
Inventories, net	649,558	674,535
Prepaid expenses and other current assets	177,918	174,349
Current assets held for sale	0	804,904
Total current assets	1,897,853	2,869,123
Property, plant, and equipment, net	1,921,733	1,765,180
Lease right-of-use assets, net	153,879	173,201
Goodwill	4,044,198	4,070,712
Intangible Assets, Net (Excluding Goodwill)	1,923,020	2,119,282
Other assets	67,679	66,199
Total assets	10,008,362	11,063,697
Current liabilities:
Accounts payable	238,298	251,723
Accrued income taxes	0	13,640
Accrued payroll and other related liabilities	160,785	164,831
Capital Lease Obligations, Current	32,451	31,239
Short-term Debt	125,000	85,938
Accrued expenses and other	334,586	319,744
Current liabilities held for sale	0	64,012
Total current liabilities	891,120	931,127
Long-term indebtedness	2,038,725	3,120,162
Deferred Income Taxes and Other Tax Liabilities, Noncurrent	453,125	479,688
Capital Lease Obligations, Noncurrent	123,717	145,828
Other Liabilities, Noncurrent	73,129	71,546
Total liabilities	3,579,816	4,748,351
Commitments and contingencies (see Note 10)
Common shares, with $0.001 par value; 500,000 authorized; 98,245 shares issued; and 98,883 shares outstanding, respectively.	4,404,687	4,543,176
Retained earnings	2,385,664	2,087,645
Accumulated other comprehensive income	(374,250)	(328,657)
Total shareholders' equity	6,416,101	6,302,164
Noncontrolling interest	12,445	13,182
Total equity	6,428,546	6,315,346
Total liabilities and equity	$ 10,008,362	$ 11,063,697

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Statement of Financial Position [Abstract]
Allowance for Doubtful Accounts Receivable, Current	$ 22,359	$ 22,984
Common Stock, Par or Stated Value Per Share	$ 0.001
Common Stock, Shares Authorized	500,000
Common Stock, Shares, Outstanding	98,245	98,883

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Revenues:
Revenues	$ 1,370,570	$ 1,297,724	$ 3,978,984	$ 3,719,314
Cost of revenues:
Total cost of revenues	760,238	737,698	2,217,431	2,084,056
Gross Profit	610,332	560,026	1,761,553	1,635,258
Operating expenses:
Selling, general, and administrative	335,450	308,295	1,000,374	943,255
Research and development	27,358	25,255	79,962	76,217
Restructuring Costs	2,231	6	30,727	2
Total operating expenses	365,039	333,556	1,111,063	1,019,474
Income from operations	245,293	226,470	650,490	615,784
Non-operating expenses, net:
Interest expense	19,094	38,948	69,146	108,243
Interest income and miscellaneous expense	(2,434)	(2,080)	(4,869)	(4,694)
Gain on sale of business and equity investment, net	(112)	0	(12,683)	0
Total non-operating expenses, net	16,548	36,868	51,594	103,549
Income before income tax expense	228,745	189,602	598,896	512,235
Income tax expense	55,384	40,999	134,200	112,254
Income from continuing operations, net of income tax	173,361	148,603	464,696	399,981
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	(76)	(7,658)	5,303	(18,900)
Net income	173,285	140,945	469,999	381,081
Less: Net Income Attributable to Noncontrolling Interest	(249)	202	1,030	1,465
Net Income (Loss) Attributable to Shareholders	$ 173,534	$ 140,743	$ 468,969	$ 379,616
Net income per common share [Abstract]
Income (Loss) from Continuing Operations, Per Basic Share	$ 1.76	$ 1.50	$ 4.70	$ 4.03
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share	0	(0.08)	0.05	(0.19)
Basic	1.76	1.42	4.75	3.84
Income (Loss) from Continuing Operations, Per Diluted Share	1.75	1.49	4.68	4.01
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share	0	(0.08)	0.05	(0.19)
Diluted	1.75	1.42	4.73	3.82
Cash dividends declared per common share outstanding	$ 0.57	$ 0.52	$ 1.66	$ 1.51
Product [Member]
Revenues:
Revenues	$ 718,337	$ 706,835	$ 2,070,538	$ 1,977,717
Cost of revenues:
Cost of Goods and Services Sold	371,736	383,651	1,080,876	1,054,507
Service [Member]
Revenues:
Revenues	652,233	590,889	1,908,446	1,741,597
Cost of revenues:
Cost of Goods and Services Sold	$ 388,502	$ 354,047	$ 1,136,555	$ 1,029,549

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Consolidated Statements of Comprehensive Income [Abstract]
Net Income	$ 173,285	$ 140,945	$ 469,999	$ 381,081
Less: Net Income Attributable to Noncontrolling Interest	(249)	202	1,030	1,465
Net Income (Loss) Attributable to Parent	173,534	140,743	468,969	379,616
Other comprehensive (loss) income
Defined benefit plan changes, (net of taxes of $(14), $17, $(42) and $52, respectively)	42	58	(79)	175
Change in cumulative foreign current translation adjustment	(208,456)	134,048	(45,514)	67,906
Total other comprehensive (loss) income	(208,414)	134,106	(45,593)	68,081
Comprehensive income	$ (34,880)	$ 274,849	$ 423,376	$ 447,697

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Statement of Comprehensive Income [Abstract]
Amortization of pension and postretirement benefits plans costs, tax	$ (14)	$ 17	$ (42)	$ 52

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income	$ 469,999	$ 381,081
Depreciation, depletion, and amortization	353,866	430,806
Deferred income taxes	(23,787)	(506)
Share-based compensation	47,606	47,588
(Gain) loss on the disposal of property, plant, and equipment, and intangibles, net	3,004	(971)
Loss on sale of businesses, net	(4,473)	0
Amortization of inventory fair value adjustments	0	4,722
Other items	(7,156)	4,536
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable, net	79,295	(18,252)
Inventories, net	(727)	(123,349)
Other current assets	(18,353)	(22,841)
Accounts payable	(7,504)	(6,097)
Accruals and other, net	(4,464)	21,750
Net cash provided by operating activities	887,306	718,467
Investing activities:
Purchases of property, plant, equipment, and intangibles, net	(299,206)	(268,829)
Proceeds from the sale of property, plant, equipment, and intangibles	4	7,375
Proceeds from Divestiture of Businesses, Net of Cash Divested	811,434	9,458
Acquisition of businesses, net of cash acquired	(53,659)	(539,758)
Net cash used in investing activities	458,573	(791,754)
Financing activities:
Repayments of Senior Debt	(80,000)	0
Repayments of Secured Debt	(638,125)	(45,000)
Proceeds (Payments) under credit facilities, net	(318,992)	265,501
Deferred financing fees and debt issuance costs	(2,316)	0
Acquisition related deferred or contingent consideration	(266)	(6,153)
Repurchases of ordinary shares	(211,058)	(11,440)
Cash dividends paid to ordinary shareholders	(163,869)	(149,173)
Payments to Noncontrolling Interests	(1,579)	(1,561)
Proceeds from issuance of equity to minority shareholders	2,532	2,883
Proceeds from (Payments for) Other Financing Activities	19,380	3,526
Net cash used in financing activities	(1,394,293)	58,583
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	(3,428)	1,932
(Decrease) increase in cash and cash equivalents	(51,842)	(12,772)
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents	$ 155,178	$ 195,585	$ 207,020	$ 208,357

CONSOLIDATED STATEMENT OF SHARE

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement - USD ($) shares in Thousands, $ in Thousands	Total	Noncontrolling Interest [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Common Stock [Member]
Beginning balance (in shares) at Mar. 31, 2023					98,629
Beginning balance at Mar. 31, 2023	$ 6,087,172	$ 9,974	$ (320,710)	$ 1,911,533	$ 4,486,375
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	381,081	1,465		379,616
Other comprehensive income	68,081		68,081
Repurchases of ordinary shares (in shares)					69
Repurchases of ordinary shares	(11,440)			(8,210)	$ (3,230)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					248
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	51,114				$ 51,114
Dividends, Common Stock, Cash	(149,173)			(149,173)
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	2,883	2,883
Distributions to noncontrolling interest	(1,561)	(1,561)
Other changes in noncontrolling interest	(58)	(58)
Ending balance at Dec. 31, 2023	6,428,099	12,703	(252,629)	2,133,766	$ 4,534,259
Ending balance (in shares) at Dec. 31, 2023					98,808
Beginning balance (in shares) at Sep. 30, 2023					98,789
Beginning balance at Sep. 30, 2023	6,189,168	11,095	(386,735)	2,045,897	$ 4,518,911
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	140,945	202		140,743
Other comprehensive income	134,106		134,106
Repurchases of ordinary shares (in shares)					12
Repurchases of ordinary shares	(2,228)			(1,497)	$ (731)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					31
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	16,079				$ 16,079
Dividends, Common Stock, Cash	(51,377)			(51,377)
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	2,883	2,883
Distributions to noncontrolling interest	(1,561)	(1,561)
Other changes in noncontrolling interest	84	84
Ending balance at Dec. 31, 2023	$ 6,428,099	12,703	(252,629)	2,133,766	$ 4,534,259
Ending balance (in shares) at Dec. 31, 2023					98,808
Beginning balance (in shares) at Mar. 31, 2024	98,883				98,883
Beginning balance at Mar. 31, 2024	$ 6,315,346	13,182	(328,657)	2,087,645	$ 4,543,176
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	469,999	1,030		468,969
Other comprehensive income	(45,593)		(45,593)
Repurchases of ordinary shares (in shares)					995
Repurchases of ordinary shares	(212,559)			(7,081)	$ (205,478)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					357
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	66,989				$ 66,989
Dividends, Common Stock, Cash	(163,869)			(163,869)
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	2,532	2,532
Distributions to noncontrolling interest	(1,579)	(1,579)
Other changes in noncontrolling interest	(2,720)	(2,720)
Ending balance at Dec. 31, 2024	$ 6,428,546	12,445	(374,250)	2,385,664	$ 4,404,687
Ending balance (in shares) at Dec. 31, 2024	98,245				98,245
Beginning balance (in shares) at Sep. 30, 2024					98,709
Beginning balance at Sep. 30, 2024	$ 6,610,462	16,973	(165,836)	2,268,326	$ 4,490,999
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	173,285	(249)		173,534
Other comprehensive income	(208,414)		(208,414)
Repurchases of ordinary shares (in shares)					471
Repurchases of ordinary shares	(101,930)			0	$ (101,930)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					7
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	15,618				$ 15,618
Dividends, Common Stock, Cash	(56,196)			(56,196)
Distributions to noncontrolling interest	(1,579)	(1,579)
Other changes in noncontrolling interest	(2,700)	(2,700)
Ending balance at Dec. 31, 2024	$ 6,428,546	$ 12,445	$ (374,250)	$ 2,385,664	$ 4,404,687
Ending balance (in shares) at Dec. 31, 2024	98,245				98,245

CONSOLIDATED STATEMENT OF SHA_2

CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Statement of Stockholders' Equity [Abstract]
Common Stock, Dividends, Per Share, Cash Paid	$ 0.57	$ 0.52	$ 1.66	$ 1.51

Nature of Operations and Summar

Nature of Operations and Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Nature of Operations	1. Nature of Operations and Summary of Significant Accounting Policies STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative products and services. These include: consumable products, such as detergents, endoscopy accessories, barrier products, instruments and tools; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment, such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as operating room (“OR”) integrati on. We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies ("AST"), and Life Sciences. Previously, we had four reportable business segments, however, as a result of the divestiture of our Dental segment, Dental is presented as discontinued operations. Historical information has been retrospectively adjusted to reflect these changes for comparability purposes, as required. We describe our business segments in Note 11 titled "Business Segment Information." Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the Securities and Exchange Commission ("SEC") on May 29, 2024. The Consolidated Balance Sheet at March 31, 2024 was derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate intercompany accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements. Discontinued Operations On April 11, 2024, the Company announced its plan to sell substantially all of the net assets of its Dental segment for total cash consideration of $787,500, subject to customary adjustments, and up to an additional $12,500 in contingent payment should the Dental business achieve certain revenue targets in fiscal 2025. The transaction was structured as an equity sale and closed on May 31, 2024. A component of an entity is reported in discontinued operations after meeting the criteria for held for sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. We analyzed the quantitative and qualitative factors relevant to the divestiture of our Dental segment and determined that those conditions for discontinued operations presentation had been met prior to March 31, 2024. The Dental segment results of operations were reclassified to income (loss) from discontinued operations in the Consolidated Statements of Income for all periods presented, and we classified the Dental segment's assets and liabilities as held for sale for the year ended March 31, 2024 in the accompanying Consolidated Balance Sheets. Due to the transaction closing in the first quarter of fiscal 2025, the held for sale assets and liabilities were classified as current as of March 31, 2024. Our Consolidated Statements of Cash Flows include the financial results of the Dental segment through the date of sale on May 31, 2024. For additional information regarding this transaction and its effect on our financial reporting, refer to Note 4 titled, "Discontinued Operations" and Note 11 titled, "Business Segment Information." Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2024 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2025. Revenue Recognition and Associated Liabilities Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2024, assets related to costs to fulfill a contract were not material to our consolidated financial statements. Refer to Note 11 titled, "Business Segment Information" for disaggregation of revenue. Product Revenues Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a distributor, dealer or group purchasing organization ("GPO") agreement. We recognize revenue for sales of products when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenues Within our Healthcare and Life Sciences segments, Service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a distributor, dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as Service revenue ratably over the contract term using a time-based input measure. Within our AST segment, Service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement, and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2025, $57,650 of the March 31, 2024 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2024, $70,181 of the March 31, 2023 deferred revenue balance was recorded as revenue. Refer to Note 8 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 8 titled, "Additional Consolidated Balance Sheet Information" for service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase, and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include orders for capital equipment and consumables where control of the products has not passed to the customer. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31, 2024, the transaction price allocated to remaining performance obligations was approximately $1,675,500. We expect to recognize approximately 53% of the transaction price within one year and approximately 36% beyond one year. The remainder has yet to be scheduled for delivery. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have not yet been adopted ASU 2023-07 "Segment Reporting (Topic 280) November 2023 The standard provides guidance to enhance disclosures related to reportable segment expenses, including requirements to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM"), the title and position of the CODM and a description of how the CODM uses the information to make decisions regarding the allocation of resources. The standard also requires disclosure of certain segment information currently required annually to be reported on an interim basis. The amendments in this standard are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. ASU 2023-09 "Income Taxes (Topic 740) Improvements to Income Tax Disclosures." December 2023 The standard provides guidance to enhance disclosures related to income taxes paid (net of refunds), requiring disaggregation by federal, state, and foreign, and disclosure of income taxes paid (net of refunds received) by individual jurisdictions that represent greater than 5% of the total. The standard also requires disclosure of income (loss) from continuing operations before income taxes, disaggregated between domestic and foreign, and income tax expense (or benefit) disaggregated by federal, state, and foreign. Finally, the standard removes the requirement for certain disclosures related to changes in unrecognized tax benefits and certain amounts of temporary differences. The amendments in this standard are effective for annual periods beginning after December 15, 2024. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. ASU 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses." November 2024 The standard provides guidance to enhance disclosures related to the disaggregation of income statement expenses. The standard requires, in the notes to the financial statements, disclosure of specified information about certain costs and expenses which includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each relevant expense caption. The standard also requires amounts that are already required to be disclosed under U.S. GAAP in the same disclosure as the other disaggregation requirements, disclosure of a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this standard are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 29, 2024. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2024.
Significant Accounting Policies	1. Nature of Operations and Summary of Significant Accounting Policies STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative products and services. These include: consumable products, such as detergents, endoscopy accessories, barrier products, instruments and tools; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment, such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as operating room (“OR”) integrati on. We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies ("AST"), and Life Sciences. Previously, we had four reportable business segments, however, as a result of the divestiture of our Dental segment, Dental is presented as discontinued operations. Historical information has been retrospectively adjusted to reflect these changes for comparability purposes, as required. We describe our business segments in Note 11 titled "Business Segment Information." Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the Securities and Exchange Commission ("SEC") on May 29, 2024. The Consolidated Balance Sheet at March 31, 2024 was derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate intercompany accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements. Discontinued Operations On April 11, 2024, the Company announced its plan to sell substantially all of the net assets of its Dental segment for total cash consideration of $787,500, subject to customary adjustments, and up to an additional $12,500 in contingent payment should the Dental business achieve certain revenue targets in fiscal 2025. The transaction was structured as an equity sale and closed on May 31, 2024. A component of an entity is reported in discontinued operations after meeting the criteria for held for sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. We analyzed the quantitative and qualitative factors relevant to the divestiture of our Dental segment and determined that those conditions for discontinued operations presentation had been met prior to March 31, 2024. The Dental segment results of operations were reclassified to income (loss) from discontinued operations in the Consolidated Statements of Income for all periods presented, and we classified the Dental segment's assets and liabilities as held for sale for the year ended March 31, 2024 in the accompanying Consolidated Balance Sheets. Due to the transaction closing in the first quarter of fiscal 2025, the held for sale assets and liabilities were classified as current as of March 31, 2024. Our Consolidated Statements of Cash Flows include the financial results of the Dental segment through the date of sale on May 31, 2024. For additional information regarding this transaction and its effect on our financial reporting, refer to Note 4 titled, "Discontinued Operations" and Note 11 titled, "Business Segment Information." Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2024 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2025. Revenue Recognition and Associated Liabilities Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2024, assets related to costs to fulfill a contract were not material to our consolidated financial statements. Refer to Note 11 titled, "Business Segment Information" for disaggregation of revenue. Product Revenues Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a distributor, dealer or group purchasing organization ("GPO") agreement. We recognize revenue for sales of products when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenues Within our Healthcare and Life Sciences segments, Service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a distributor, dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as Service revenue ratably over the contract term using a time-based input measure. Within our AST segment, Service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement, and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2025, $57,650 of the March 31, 2024 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2024, $70,181 of the March 31, 2023 deferred revenue balance was recorded as revenue. Refer to Note 8 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 8 titled, "Additional Consolidated Balance Sheet Information" for service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase, and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include orders for capital equipment and consumables where control of the products has not passed to the customer. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31, 2024, the transaction price allocated to remaining performance obligations was approximately $1,675,500. We expect to recognize approximately 53% of the transaction price within one year and approximately 36% beyond one year. The remainder has yet to be scheduled for delivery. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have not yet been adopted ASU 2023-07 "Segment Reporting (Topic 280) November 2023 The standard provides guidance to enhance disclosures related to reportable segment expenses, including requirements to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM"), the title and position of the CODM and a description of how the CODM uses the information to make decisions regarding the allocation of resources. The standard also requires disclosure of certain segment information currently required annually to be reported on an interim basis. The amendments in this standard are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. ASU 2023-09 "Income Taxes (Topic 740) Improvements to Income Tax Disclosures." December 2023 The standard provides guidance to enhance disclosures related to income taxes paid (net of refunds), requiring disaggregation by federal, state, and foreign, and disclosure of income taxes paid (net of refunds received) by individual jurisdictions that represent greater than 5% of the total. The standard also requires disclosure of income (loss) from continuing operations before income taxes, disaggregated between domestic and foreign, and income tax expense (or benefit) disaggregated by federal, state, and foreign. Finally, the standard removes the requirement for certain disclosures related to changes in unrecognized tax benefits and certain amounts of temporary differences. The amendments in this standard are effective for annual periods beginning after December 15, 2024. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. ASU 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses." November 2024 The standard provides guidance to enhance disclosures related to the disaggregation of income statement expenses. The standard requires, in the notes to the financial statements, disclosure of specified information about certain costs and expenses which includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each relevant expense caption. The standard also requires amounts that are already required to be disclosed under U.S. GAAP in the same disclosure as the other disaggregation requirements, disclosure of a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this standard are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 29, 2024. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2024.

Restructuring

Restructuring	9 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring	2. Restructuring In May 2024, we adopted and announced a targeted restructuring plan (the "Restructuring Plan"). This plan includes a strategic shift in our approach to the Healthcare surgical business in Europe, as well as other actions including the impairment of an internally developed X-ray accelerator, product rationalizations and facility consolidations. Fewer than 300 positions are being eliminated. These restructuring actions are designed to enhance profitability and improve efficiency, and we expect these actions to be substantially complete by the end of fiscal 2025. The following tables summarize our total pre-tax restructuring expenses recorded in fiscal 2025 related to the Restructuring Plan: Three Months Ended December 31, Nine Months Ended December 31, Restructuring Plan Severance and other compensation related costs $ — $ 23,285 Lease and other contract termination and other costs 2,231 6,192 Product rationalization (1) — 2,382 Accelerated depreciation and amortization — 1,250 Total Restructuring Expense $ 2,231 $ 33,109 (1) Recorded in Cost of revenues on the Consolidated Statements of Income. The Restructuring Plan expenses incurred during the three and nine months ended December 31, 2024 primarily related to actions taken within our Healthcare segment. Total pre-tax restructuring expense of $77,499 has been recorded relating to the Restructuring Plan since inception, of which $20,702 has been recorded in Cost of revenues. We expect to incur additional costs, primarily for lease and other contract termination and other costs, of approximately $20,000, predominantly through the remainder of fiscal 2025. Liabilities related to restructuring activities are recorded as current liabilities in the accompanying Consolidated Balance Sheets within "Accrued payroll and other related liabilities" and "Accrued expenses and other." The following table summarizes our restructuring liability balances: Restructuring Plan Balance at March 31, 2024 $ 678 Fiscal 2025 Charges 29,477 Payments (12,440) Balance at December 31, 2024 $ 17,715

Business Acquisitions and Dives

Business Acquisitions and Divestitures	9 Months Ended
	Dec. 31, 2024
Business Acquisitions and Divestitures [Abstract]
Business Combination Disclosure	3. Business Acquisitions and Divestitures Acquisitions During the first nine months of fiscal 2025, we completed several tuck-in acquisitions which continued to expand our product and service offerings in the Healthcare and AST segments. Total aggregate consideration was approximately $53,659. On August 2, 2023 , we purchased the surgical instrumentation, laparoscopic instrumentation and sterilization container assets from Becton, Dickinson and Company (NYSE: BDX) ("BD"). The acquired assets from BD were integrated into our Healthcare segment. The purchase price of the BD acquisition was $539,758. The acquisition also qualified for a tax benefit related to tax deductible goodwill, with a present value of approximately $60,000. The purchase price of the acquisition was financed with borrowings from our Previous Revolving Credit Facility. For more information, refer to Note 7 titled, " Debt." The table below summarizes the allocation of the purchase price to the net assets acquired from BD based on fair values at the acquisition date. September 30, 2023 Adjustments (2) Final Inventory 27,006 4,821 31,827 Property, plant, and equipment 6,755 1,109 7,864 Lease right-of-use assets, net — 1,737 1,737 Intangible assets (1) 303,598 (598) 303,000 Goodwill 202,399 (5,332) 197,067 Total assets acquired 539,758 1,737 541,495 Lease obligations — 1,737 1,737 Total liabilities assumed — 1,737 1,737 Net assets acquired $ 539,758 $ — $ 539,758 (1) Includes estimated fair values of $238,000 for Customer relationships ( 13 years estimated useful life), $50,000 for Patents and technology ( 13 years estimated useful life), and $15,000 for Trademarks and trade names ( 15 years estimated useful life) as of the acquisition date. (2) No additional adjustments made during fiscal 2025. Acquisition and integration expenses totaled $3,756 and $9,215 for the three and nine months ended December 31, 2024, respectively. Acquisition and integration expenses totaled $6,263 and $24,308 for the three and nine months ended December 31, 2023, respectively. The decrease in acquisition and integration expenses for the three and nine months ended December 31, 2024 is primarily due to charges related to the acquisition of assets from BD and a fair value adjustment related to a building held for sale from a previous acquisition during fiscal 2024. Acquisition and integration expenses are reported in the Selling, general and administrative expenses line of our Consolidated Statements of Income and include, but are not limited to, investment banker, advisory, legal and other professional fees, and certain employee-related expenses. Divestitures On April 11, 2024, the Company announced its plan to sell its Dental segment for total cash consideration of $787,500, subject to customary adjustments, and up to an additional $12,500 in contingent payment should the Dental business achieve certain revenue targets in fiscal 2025. The transaction was structured as an equity sale and closed on May 31, 2024. The disposal of the Dental segment met the criteria to be presented as a discontinued operation. For more information refer to Note 4 titled "Discontinued Operations." On April 1, 2024, we completed the sale of the Controlled Environment Certification Services business. We recorded net proceeds of $41,894 and recognized a pre-tax gain on the sale of $19,263 in fiscal 2025. The business generated approximately $35,000 in revenues in fiscal 2024.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	4. Discontinued Operations On April 11, 2024, the Company announced its plan to sell substantially all of the net assets of its Dental segment for total cash consideration of $787,500, subject to customary adjustments, and up to an additional $12,500 in contingent payment should the Dental business achieve certain revenue targets in fiscal 2025. The transaction was structured as an equity sale and closed on May 31, 2024. A component of an entity is reported in discontinued operations after meeting the criteria for held for sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. We analyzed the quantitative and qualitative factors relevant to the divestiture of our Dental segment and determined that those conditions for discontinued operations presentation had been met prior to March 31, 2024. The Dental segment results of operations were reclassified to income (loss) from discontinued operations in the Consolidated Statements of Income for all periods presented, and we classified the Dental segment's assets and liabilities as held for sale as of March 31, 2024 in the accompanying Consolidated Balance Sheets. Due to the transaction closing in the first quarter of fiscal 2025, the held for sale assets and liabilities were classified as current as of March 31, 2024. Our Consolidated Statements of Cash Flows include the financial results of the Dental segment through the date of sale on May 31, 2024. A majority of the proceeds received from the sale were utilized to pay off existing debt. The following table summarizes the major classes of assets and liabilities of the Dental business segment that were classified as held for sale in the Consolidated Balance Sheets as of March 31, 2024: March 31, Assets Assets held-for-sale: Accounts receivable, net $ 48,590 Inventories, net 89,345 Property, plant, and equipment, net 73,395 Lease right-of-use assets, net 22,822 Intangibles, net 770,731 Prepaid expenses and other assets 2,953 Loss accrued on classification as held for sale (202,932) Total assets held-for-sale $ 804,904 Liabilities Liabilities held-for-sale: Accounts payable $ 10,580 Accrued income taxes 433 Accrued payroll and other related liabilities 13,683 Lease obligations 23,722 Accrued expenses and other 15,594 Total liabilities held-for-sale $ 64,012 The following table summarizes the major line items constituting pre-tax income of discontinued operations associated with the Dental segment for the three and nine months ending December 31, 2024 and 2023: Three Months Ended December 31, 2024 Nine Months Ended December 31, 2024 2023 2024 2023 Revenues: Product $ — $ 97,921 $ 63,936 $ 303,233 Cost of revenues: Product — 55,354 35,146 168,908 Gross profit: — 42,567 28,790 134,325 Operating expenses: Selling, general, and administrative — 52,223 13,466 156,972 Research and development — 658 369 2,242 (Loss) income from operations (1) — (10,314) 14,955 (24,889) Non-operating expenses (income), net — (1) 1 (11) Pre-tax loss on sale (97) — (8,210) — (Loss) income before income tax expense (97) (10,313) 6,744 (24,878) Income tax (benefit) expense (21) (2,655) 1,441 (5,978) (Loss) income from discontinued operations, net of income tax (76) (7,658) 5,303 (18,900) (1) Income from operations for the nine month period ended December 31, 2024 includes two months of operating results prior to the transaction close on May 31, 2024 and excludes depreciation and amortization of property, plant, equipment, and intangible assets subsequent to the held for sale classification as of March 2, 2024. The effective income tax rates for the three month periods ending December 31, 2024 and 2023 from discontinued operations were 21.6% and 25.7%, respectively. The effective income tax rates for the nine month periods ending December 31, 2024 and 2023 from discontinued operations were 21.4% and 24.0%, respectively. Significant non-cash operating items and capital expenditures related to discontinued operations are reflected in the statement of cash flows as follows: Nine Months Ended December 31, 2024 2023 Operating activities of discontinued operations: Depreciation, depletion, and amortization $ — $ 90,847 Investing activities of discontinued operations: Purchases of property, plant, equipment, and intangibles, net $ (433) $ (6,722)

Inventories, Net (Notes)

Inventories, Net (Notes)	9 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Inventories, Net	5. Inventories, Net Inventories are stated at the lower of their cost and net realizable value determined by the first-in, first-out (“FIFO”) cost method. Inventory costs include material, labor, and overhead . Inventories, net consisted of the following: December 31, March 31, Raw materials $ 229,468 $ 245,942 Work in process 94,262 98,304 Finished goods 367,347 374,182 Reserve for excess and obsolete inventory (41,519) (43,893) Inventories, net $ 649,558 $ 674,535

Property, Plant and Equipment (

Property, Plant and Equipment (Notes)	9 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	6. Property, Plant, and Equipment Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 105,182 $ 90,134 Buildings and leasehold improvements 783,562 724,492 Machinery and equipment 1,184,474 1,075,082 Information systems 285,433 256,671 Radioisotope 737,146 692,642 Construction in progress (1) 509,802 500,106 Total property, plant, and equipment 3,605,599 3,339,127 Less: accumulated depreciation and depletion (1,683,866) (1,573,947) Property, plant, and equipment, net $ 1,921,733 $ 1,765,180 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Notes)

Debt (Notes)	9 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Debt	7. Debt Indebtedness was as follows: December 31, March 31, Short-term debt Term loan, current portion $ — $ 41,250 Delayed draw term loan, current portion — 44,688 Private Placement Senior Notes 125,000 — Total short-term debt $ 125,000 $ 85,938 Long-term debt Private Placement Senior Notes $ 542,352 $ 751,433 Revolving Credit Facility 162,014 484,529 Deferred financing costs (15,641) (17,988) Term loan — 3,750 Delayed draw term loan — 548,438 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 2,038,725 $ 3,120,162 Total debt $ 2,163,725 $ 3,206,100 On October 7, 2024, STERIS plc (“Parent”), STERIS Corporation, STERIS Limited, and STERIS Irish FinCo Unlimited Company (“FinCo”), each as a borrower and guarantor, entered into a credit agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as administrative agent (the “Revolving Credit Agreement”) providing for a $1,100,000 revolving credit facility (the “Revolving Credit Facility”), which replaced a prior credit agreement, dated as of March 19, 2021 (the “Previous Revolving Credit Facility”). The Revolving Credit Agreement provides for revolving credit borrowings, swing line borrowings and letters of credit, with sublimits for swing line borrowings and letters of credit. The Revolving Credit Agreement may be increased in specified circumstances by up to $625,000 in the discretion of the lenders. The Revolving Credit Agreement matures on the date that is five years after October 7, 2024, and all unpaid borrowings, together with accrued and unpaid interest thereon, are repayable on that date. The Revolving Credit Facility bears interest from time to time, at either the Base Rate or the Relevant Rate, as defined in and calculated under and as in effect from time to time under the Revolving Credit Agreement, plus the Applicable Margin, as defined in the Revolving Credit Agreement. The Applicable Margin is determined based on the Debt Rating of Parent, as defined in the Revolving Credit Agreement. Base Rate Advances are payable quarterly in arrears and Term Benchmark Advances are payable at the end of the relevant interest period therefor, but in no event less frequently than every three months. Swingline borrowings bear interest at a rate to be agreed by the applicable swingline lender and the applicable borrower, subject to a cap in the case of swingline borrowings denominated in U.S. Dollars equal to the Base Rate plus the Applicable Margin for Base Rate Advances plus the Facility Fee. There is no premium or penalty for prepayment of Base Rate Advances, but prepayments of Term Benchmark Advances are generally subject to a breakage fee. Advances may be extended in U.S. Dollars or in specified alternative currencies (“Alternative Currency Advances”). Alternative Currency Advances are limited in the aggregate to the equivalent of $625,000 . Additional information regarding our indebtedness is included in the notes to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on

Additional Consolidated Balance

Additional Consolidated Balance Sheets Information (Notes)	9 Months Ended
	Dec. 31, 2024
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	8. Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 65,256 $ 48,152 Accrued vacation/paid time off 18,215 16,140 Accrued bonuses 48,660 61,669 Accrued employee commissions 25,711 35,980 Other postretirement benefit obligations-current portion 994 994 Other employee benefit plans obligations-current portion 1,949 1,896 Total accrued payroll and other related liabilities $ 160,785 $ 164,831 Accrued expenses and other: Deferred revenues $ 80,033 $ 70,460 Service liabilities 97,306 92,590 Self-insured risk reserves-current portion 19,742 13,303 Accrued dealer commissions 34,705 33,277 Accrued warranty 14,732 15,388 Asset retirement obligation-current portion 560 510 Accrued interest 17,726 11,109 Other 69,782 83,107 Total accrued expenses and other $ 334,586 $ 319,744 Other liabilities: Self-insured risk reserves-long-term portion $ 21,647 $ 21,646 Other postretirement benefit obligations-long-term portion 5,372 5,159 Defined benefit pension plans obligations-long-term portion 3,166 2,727 Other employee benefit plans obligations-long-term portion 1,423 1,321 Accrued long-term income taxes 6,527 6,508 Asset retirement obligation-long-term portion 13,369 13,148 Other 21,625 21,037 Total other liabilities $ 73,129 $ 71,546

Income Tax Expense (Notes)

Income Tax Expense (Notes)	9 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Tax Expense	9. Income Taxes Our effective tax rate is affected by (i) the tax rates in Ireland (our country of domicile), the United States, and other jurisdictions in which we operate, and (ii) the relative amount of income before income taxes by geography. The effective income tax rates for the three month periods ended December 31, 2024 and 2023 from continuing operations were 24.2% and 21.6%, respectively. The effective income tax rates for the nine month periods ended December 31, 2024 and 2023 from continuing operations were 22.4% and 21.9%, respectively. The fiscal 2025 effective tax rates increased when compared to fiscal 2024, primarily due to unfavorable discrete items recorded in fiscal 2025 and changes in geographic mix of projected profits. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2018 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2018. We remain subject to tax authority audits in various jurisdictions wherever we do business. In the fourth quarter of fiscal 2021, we completed an appeals process with the U.S. Internal Revenue Service (the “IRS”) regarding proposed audit adjustments related to deductibility of interest paid on intercompany debt for fiscal years 2016 through 2017. An agreement was reached on final interest rates, which also impacted subsequent years through 2020. The total federal, state, and local tax impact of the settlement including interest is approximately $12,000 for the fiscal years 2016 through 2020, materially all of which has been paid through December 31, 2024.

Contingencies (Notes)

Contingencies (Notes)	9 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies	10. Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, gases, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed above). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, and we may also have contractual indemnification rights against certain liabilities, but there can be no assurance that either will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. Civil, criminal, regulatory or other proceedings involving our products or services, including the matters discussed herein, could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially affect our business, performance, prospects, value, financial condition, and results of operations. Further, the Company may incur material defense costs as a result of such proceedings, which may also divert management attention from other priorities. From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. Ethylene Oxide Litigation in Illinois A subsidiary of the Company has been sued in Illinois state court by individual plaintiffs who work or reside near a facility in Lake County, Illinois, where the subsidiary provided sterilization services using ethylene oxide (“EO”) from January 2005 to September 2008. The plaintiffs have filed separate suits in which each alleges that they have been diagnosed with one or more types of cancer, allegedly resulting from exposure to EO emissions from the facility into the ambient air. As of December 31, 2024, approximately 250 individual plaintiffs have filed such suits asserting individual personal injury claims and seeking compensatory and, if subsequently permitted by the court, punitive damages. The first trial of a plaintiff’s claims concluded in a mistrial on January 17, 2025 and is scheduled for retrial in May 2025. The Company disputes the allegations, is vigorously defending itself in these matters, and is pursuing potential contribution and indemnity from other parties. Nonetheless, management believes that based on the number of cases and the overall cost of defense, a loss is reasonably possible; however, a range of loss cannot be reasonably estimated at this time because the evaluation of each case is highly fact-driven, subject to lengthy court proceedings, and impacted by each plaintiff's alleged disease, time and proximity of exposure, and other factors. No amounts have been accrued in our consolidated financial statements with respect to any loss contingencies in this matter. We believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Additional Information For additional information, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 29, 2024, Item 1 titled "Business - Information with respect to our Business in General - Government Regulation" and the "Risk Factors" in Item 1A titled "Product and service related regulations and claims." We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 9 to our consolidated financial statements titled, “Income Taxes” in this Quarterly Report on Form 10-Q.

Business Segment Information (N

Business Segment Information (Notes)	9 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Business Segment Information	11. Business Segment Information We operate and report our financial information in three reportable business segments: Healthcare, AST, and Life Sciences. Previously, we had four reportable business segments, however, as a result of the divestiture of our Dental segment, Dental is presented as discontinued operations. Historical information has been retrospectively adjusted to reflect these changes for comparability, as required. For more information, refer to Note 4 titled, "Discontinued Operations." Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection prevention consumables and capital equipment, as well as services to maintain that equipment; to the repair of re-usable procedural instruments; to outsourced instrument reprocessing services. In addition, our procedural solutions also include endoscopy accessories, instruments, and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas. Our AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization. Our Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Our portfolio includes a full suite of capital equipment, consumable products, equipment maintenance and specialty services. We d isclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. For the three and nine months e nded December 31, 2024 and 2023 , revenues from a single Customer did not represent ten percent or more of the Healthcare, AST or Life Sciences segment revenues. A dditional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 29, 2024. The following table compares business segment revenues and business segment and Corporate operating income for the three and nine months e nded December 31, 2024 and 2023: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Revenues: Healthcare $ 976,044 $ 916,227 $ 2,821,495 $ 2,605,157 AST 258,144 234,931 764,684 703,083 Life Sciences 136,382 146,566 392,805 411,074 Total revenues $ 1,370,570 $ 1,297,724 $ 3,978,984 $ 3,719,314 Income (loss) from operations before adjustments: Healthcare $ 246,917 $ 223,898 $ 691,810 $ 626,134 AST 115,758 105,156 343,374 325,529 Life Sciences 58,133 56,738 164,417 156,863 Corporate (100,843) (81,559) (299,720) (260,452) Total income from operations before adjustments $ 319,965 $ 304,233 $ 899,881 $ 848,074 Less: Adjustments Amortization of acquired intangible assets (1) $ 67,243 $ 64,724 $ 202,875 $ 198,662 Acquisition and integration related charges (2) 3,756 6,263 9,215 24,308 Tax restructuring costs (3) 97 643 54 652 Amortization of inventory and property "step up" to fair value (1) 1,345 6,127 4,138 8,666 Restructuring charges (4) 2,231 6 33,109 2 Income from operations $ 245,293 $ 226,470 $ 650,490 $ 615,784 (1) For more information regarding our recent acquisitions and divestitures, refer to Note 3 titled, "Business Acquisitions and Divestitures." (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) For more information regarding our restructuring efforts, refer to Note 2 titled, "Restructuring ." Additional information regarding our fiscal 2025 and fiscal 2024 revenue is disclosed in the following tables: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Healthcare: Capital equipment $ 254,804 $ 266,838 $ 719,175 $ 759,842 Consumables 358,233 329,435 1,043,294 915,741 Service 363,007 319,954 1,059,026 929,574 Total Healthcare Revenues $ 976,044 $ 916,227 $ 2,821,495 $ 2,605,157 AST: Capital equipment $ 5,004 $ 5,241 $ 14,897 $ 7,869 Service 253,140 229,690 749,787 695,214 Total AST Revenues $ 258,144 $ 234,931 $ 764,684 $ 703,083 Life Sciences: Capital equipment $ 31,063 $ 44,836 $ 80,551 $ 111,265 Consumables 68,676 60,072 210,619 181,179 Service 36,643 41,658 101,635 118,630 Total Life Sciences Revenues $ 136,382 $ 146,566 $ 392,805 $ 411,074 Total Revenues $ 1,370,570 $ 1,297,724 $ 3,978,984 $ 3,719,314 Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Revenues: Ireland $ 24,117 $ 19,601 $ 69,113 $ 60,037 United States 1,002,586 949,957 2,929,004 2,715,397 Other locations 343,867 328,166 980,867 943,880 Total Revenues $ 1,370,570 $ 1,297,724 $ 3,978,984 $ 3,719,314

Shares and Preferred Shares (No

Shares and Preferred Shares (Notes)	9 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	12. Shares and Preferred Shares Ordinary shares We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. Income from continuing operations is used as the benchmark to determine whether share equivalents are dilutive or anti-dilutive. Earnings per share is calculated independently for earnings per share from continuing operations and earnings per share from discontinued operations. The sum of earnings per share from continuing operations and earnings per share from discontinued operations may not equal total company earnings per share due to rounding. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share: Three Months Ended December 31, Nine Months Ended December 31, Denominator (shares in thousands): 2024 2023 2024 2023 Weighted average shares outstanding—basic 98,490 98,802 98,676 98,765 Dilutive effect of share equivalents 452 552 498 568 Weighted average shares outstanding and share equivalents—diluted 98,942 99,354 99,174 99,333 Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, (shares in thousands) 2024 2023 2024 2023 Number of share options 794 654 686 649 Additional Authorized Shares The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.

Equity

Equity	9 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Treasury Stock	13. Repurchases of Ordinary Shares On May 3, 2023 our Board of Directors terminated the previous share repurchase program and authorized a new share repurchase program for the purchase of up to $500,000 (net of taxes, fees and commissions). As of December 31, 2024, there was $300,000 (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date. Under the repurchase program, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. During the first nine months of fiscal 2025, we repurchased 907,158 of our ordinary shares for the aggregate amount of $200,000 (net of excise taxes, fees, and commissions) pursuant to authorizations, under the share repurchase program. During the first nine months of fiscal 2024, we had no share repurchase activity. During the first nine months of fiscal 2025, we obtained 87,436 of our ordinary shares in the aggregate amount of $11,040 in connection with share-based compensation award programs. During the first nine months of fiscal 2024, we obtained 69,276 of our ordinary shares in the aggregate amount of $11,440 in connection with share-based compensation award programs.

Share-Based Compensation (Notes

Share-Based Compensation (Notes)	9 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	14. Share-Based Compensation We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Board of Directors or Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares. In recent years, grants have been limited to stock options, restricted shares, and restricted share units. Stock option awards to employees generally vest and become nonforfeitable in increments of 25% per year over a four-year period, with full vesting four years after the date of grant. Historically, restricted stock awards to employee recipients generally cliff vested on the fourth anniversary of the grant date if the recipient remained in continuous employment through that date. Beginning with fiscal 2024 grants, Company restricted stock (and restricted stock units) generally cliff vest over a three year period after the grant date. However, employees who are grantees of restricted stock and have attained age 55 and been employed for at least five years at the time of the grant or meet these criteria during the term of the grant and are employed in the U.S. or in a few other foreign jurisdictions, or employees who have 25 years of service at the time of grant or meet that criterion during the term of the grant, will be subject to installment vesting rules over the applicable vesting period. Awards to certain employees in the U.S. or a few other jurisdictions may provide for continued vesting after “retirement,” if certain conditions are met. As of December 31, 2024, 2,027,503 ordinary shares remained available for grant under the long-term incentive plan. The fair value of share-based stock option compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as Cost of revenues or Selling, general, and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted average assumptions were used for options granted during the first nine months of fiscal 2025 and 2024: Fiscal 2025 Fiscal 2024 Risk-free interest rate 4.21 % 3.59 % Expected life of options 6.1 years 6.0 years Expected dividend yield of stock 0.94 % 1.08 % Expected volatility of stock 28.42 % 27.92 % The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.07% and 2.22% was applied in fiscal 2025 and 2024, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2024 1,869,871 $ 168.22 Granted 217,426 250.76 Exercised (190,441) 107.21 Forfeited (9,976) 237.01 Expired (512) 250.06 Outstanding at December 31, 2024 1,886,368 $ 183.51 5.9 years $ 67,166 Exercisable at December 31, 2024 1,334,958 $ 161.48 4.9 years $ 67,166 We estimate that 541,677 of the non-vested stock options outstanding at December 31, 2024 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $205.56 closing price of our ordinary shares on December 31, 2024 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of our ordinary shares. The total intrinsic value of stock options exercised during the first nine months of fiscal 2025 and fiscal 2024 was $24,647 and $8,350, respectively. Net cash proceeds from the exercise of stock options were $19,380 and $3,526 for the first nine months of fiscal 2025 and fiscal 2024, respectively. The weighted average grant date fair value of stock option grants was $67.81 and $54.60 for the first nine months of fiscal 2025 and fiscal 2024, respectively. A summary of the non-vested restricted share and share unit activity is presented below: Number of Number of Restricted Share Units Weighted Average Non-vested at March 31, 2024 463,381 28,348 $ 200.04 Granted 160,789 16,865 228.97 Vested (131,250) (12,248) 186.21 Forfeited (38,911) (1,792) 207.88 Non-vested at December 31, 2024 454,009 31,173 $ 214.16 Restricted shares and restricted share unit grants are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during the first nine months of fiscal 2025 at the time of grant was $26,891. As of December 31, 2024, there was a total of $60,400 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 1.7 years.

Financial and Other Guarantees(

Financial and Other Guarantees(Notes)	9 Months Ended
	Dec. 31, 2024
Product Warranties Disclosures [Abstract]
Product Warranty Disclosure	15. Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time Product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first nine months of fiscal 2025 were as follows: Warranties Balance at March 31, 2024 $ 15,388 Warranties issued during the period 12,732 Settlements made during the period (13,388) Balance at December 31, 2024 $ 14,732

Deritvatives and Hedging (Notes

Deritvatives and Hedging (Notes)	9 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure	16. Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including intercompany transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our Cost of revenues. During the third quarter of fiscal 2025, we also held forward foreign currency contracts to hedge a portion of our expected non-U.S. dollar-denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature in fiscal 2025. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At December 31, 2024, we held net foreign currency forward contracts to buy 40.0 million British pounds sterling, 14.0 million Canadian dollars, and 49.0 million Mexican pesos; and to sell 15.0 million Australian dollars and 8.4 million euros. At December 31, 2024, we held commodity swap contracts to buy 197.3 thousand pounds of nickel. Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location December 31, 2024 March 31, 2024 December 31, 2024 March 31, 2024 Prepaid & other $ 489 $ 208 $ — $ — Accrued expenses and other $ — $ — $ 772 $ 1,014 The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Foreign currency forward contracts Selling, general and administrative $ (2,642) $ (292) $ 259 $ 1,226 Commodity swap contracts Cost of revenues $ (342) $ (316) $ (193) $ (1,708)

Fair Value Measurements (Notes)

Fair Value Measurements (Notes)	9 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Disclosures	17. Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at December 31, 2024 and March 31, 2024: Fair Value Measurements Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 December 31, March 31, December 31, March 31, December 31, March 31, December 31, March 31, Assets: Cash and cash equivalents $ 155,178 $ 207,020 $ 155,178 $ 207,020 $ — $ — $ — $ — Forward and swap contracts (1) 489 208 — — 489 208 — — Equity investments (2) 1,240 4,767 1,240 4,767 — — — — Other investments 2,803 2,902 2,803 2,902 — — — — Liabilities: Forward and swap contracts (1) $ 772 $ 1,014 $ — $ — $ 772 $ 1,014 $ — $ — Deferred compensation plans (2) 1,272 1,186 1,272 1,186 — — — — Debt (3) 2,163,725 3,206,100 — — 1,848,204 2,895,784 — — Contingent consideration obligations (4) 11,625 11,000 — — — — 11,625 11,000 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). Changes in the fair value of these investments are recorded in the "Interest and miscellaneous income" line of the Consolidated Statement of Income. During the first three and nine months of fiscal 2025, we recorded gains of $774 and $878, respectively, related to these investments. During the first three and nine months of fiscal 2024, we recorded gains of $881 and $1,019, respectively, related to these investments. We also held other equity investments in which we recorded a loss during the second quarter of fiscal 2025 in the "Gain on sale of business and equity investment, net" line of the Consolidated Statement of Income. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. The fair values of our Senior Public Notes are estimated using quoted market prices for the Senior Public Notes. (4) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2024 are summarized as follows: Contingent Consideration Balance at March 31, 2024 $ 11,000 Additions 671 Payments (60) Currency translation adjustments 14 Balance at December 31, 2024 $ 11,625

Reclassifications out of Accumu

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes)	9 Months Ended
	Dec. 31, 2024
Reclassifications out of AOCI [Abstract]
Comprehensive Income (Loss) Note [Text Block]	18. Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2024 and 2023 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Loss Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ (845) $ (724) $ (164,991) $ (327,933) $ (165,836) $ (328,657) Other Comprehensive Income (Loss) before reclassifications 118 147 (208,418) (72,569) (208,300) (72,422) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) (76) (226) (38) 27,055 (114) 26,829 Net current-period Other Comprehensive Income (Loss) 42 (79) (208,456) (45,514) (208,414) (45,593) Balance at December 31, 2024 $ (803) $ (803) $ (373,447) $ (373,447) $ (374,250) $ (374,250) (1) The amortization (gain) of defined benefit pension items is reported in the Interest and miscellaneous (income) expense line of our Consolidated Statements of Income. (2) The amounts previously recognized in currency translation adjustments related to our Dental business were reclassified when realized and included in the calculation of the loss on sale, net of previous accrued losses, within (Loss) income from discontinued operations, net of tax, for the nine month period ended December 31, 2024. Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Loss Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 129 $ 12 $ (386,864) $ (320,722) $ (386,735) $ (320,710) Other Comprehensive Income (Loss) before reclassifications 408 1,160 134,048 67,906 134,456 69,066 Amounts reclassified from Accumulated Other Comprehensive Loss (350) (985) — — (350) (985) Net current-period Other Comprehensive Income (Loss) 58 175 134,048 67,906 134,106 68,081 Balance at December 31, 2023 $ 187 $ 187 $ (252,816) $ (252,816) $ (252,629) $ (252,629) 1)

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss) Attributable to Parent	$ 173,534	$ 140,743	$ 468,969	$ 379,616

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Nature of Operations and Summ_2

Nature of Operations and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate intercompany accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements.
Discontinued Operations	Discontinued Operations On April 11, 2024, the Company announced its plan to sell substantially all of the net assets of its Dental segment for total cash consideration of $787,500, subject to customary adjustments, and up to an additional $12,500 in contingent payment should the Dental business achieve certain revenue targets in fiscal 2025. The transaction was structured as an equity sale and closed on May 31, 2024. A component of an entity is reported in discontinued operations after meeting the criteria for held for sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. We analyzed the quantitative and qualitative factors relevant to the divestiture of our Dental segment and determined that those conditions for discontinued operations presentation had been met prior to March 31, 2024. The Dental segment results of operations were reclassified to income (loss) from discontinued operations in the Consolidated Statements of Income for all periods presented, and we classified the Dental segment's assets and liabilities as held for sale for the year ended March 31, 2024 in the accompanying Consolidated Balance Sheets. Due to the transaction closing in the first quarter of fiscal 2025, the held for sale assets and liabilities were classified as current as of March 31, 2024. Our Consolidated Statements of Cash Flows include the financial results of the Dental segment through the date of sale on May 31, 2024. For additional information regarding this transaction and its effect on our financial reporting, refer to Note 4 titled, "Discontinued Operations" and Note 11 titled, "Business Segment Information."
Use of Estimates	Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three and nine month periods ended December 31, 2024 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2025.
Revenue	Revenue Recognition and Associated Liabilities Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At December 31, 2024, assets related to costs to fulfill a contract were not material to our consolidated financial statements. Refer to Note 11 titled, "Business Segment Information" for disaggregation of revenue. Product Revenues Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a distributor, dealer or group purchasing organization ("GPO") agreement. We recognize revenue for sales of products when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenues Within our Healthcare and Life Sciences segments, Service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a distributor, dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as Service revenue ratably over the contract term using a time-based input measure. Within our AST segment, Service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement, and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first nine months of fiscal 2025, $57,650 of the March 31, 2024 deferred revenue balance was recorded as revenue. During the first nine months of fiscal 2024, $70,181 of the March 31, 2023 deferred revenue balance was recorded as revenue. Refer to Note 8 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances. Service Liabilities Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 8 titled, "Additional Consolidated Balance Sheet Information" for service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase, and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include orders for capital equipment and consumables where control of the products has not passed to the customer. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of December 31, 2024, the transaction price allocated to remaining performance obligations was approximately $1,675,500. We expect to recognize
Recently Issued Accounting Standards Impacting the Company	Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have not yet been adopted ASU 2023-07 "Segment Reporting (Topic 280) November 2023 The standard provides guidance to enhance disclosures related to reportable segment expenses, including requirements to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM"), the title and position of the CODM and a description of how the CODM uses the information to make decisions regarding the allocation of resources. The standard also requires disclosure of certain segment information currently required annually to be reported on an interim basis. The amendments in this standard are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. ASU 2023-09 "Income Taxes (Topic 740) Improvements to Income Tax Disclosures." December 2023 The standard provides guidance to enhance disclosures related to income taxes paid (net of refunds), requiring disaggregation by federal, state, and foreign, and disclosure of income taxes paid (net of refunds received) by individual jurisdictions that represent greater than 5% of the total. The standard also requires disclosure of income (loss) from continuing operations before income taxes, disaggregated between domestic and foreign, and income tax expense (or benefit) disaggregated by federal, state, and foreign. Finally, the standard removes the requirement for certain disclosures related to changes in unrecognized tax benefits and certain amounts of temporary differences. The amendments in this standard are effective for annual periods beginning after December 15, 2024. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. ASU 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses." November 2024 The standard provides guidance to enhance disclosures related to the disaggregation of income statement expenses. The standard requires, in the notes to the financial statements, disclosure of specified information about certain costs and expenses which includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each relevant expense caption. The standard also requires amounts that are already required to be disclosed under U.S. GAAP in the same disclosure as the other disaggregation requirements, disclosure of a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this standard are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 29, 2024. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2024.

Nature of Operations and Summ_3

Nature of Operations and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
New Accounting Pronouncement, Early Adoption	Recently Issued Accounting Standards Impacting the Company are presented in the following table: Standard Date of Issuance Description Date of Adoption Effect on the financial statements or other significant matters Standards that have not yet been adopted ASU 2023-07 "Segment Reporting (Topic 280) November 2023 The standard provides guidance to enhance disclosures related to reportable segment expenses, including requirements to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM"), the title and position of the CODM and a description of how the CODM uses the information to make decisions regarding the allocation of resources. The standard also requires disclosure of certain segment information currently required annually to be reported on an interim basis. The amendments in this standard are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. ASU 2023-09 "Income Taxes (Topic 740) Improvements to Income Tax Disclosures." December 2023 The standard provides guidance to enhance disclosures related to income taxes paid (net of refunds), requiring disaggregation by federal, state, and foreign, and disclosure of income taxes paid (net of refunds received) by individual jurisdictions that represent greater than 5% of the total. The standard also requires disclosure of income (loss) from continuing operations before income taxes, disaggregated between domestic and foreign, and income tax expense (or benefit) disaggregated by federal, state, and foreign. Finally, the standard removes the requirement for certain disclosures related to changes in unrecognized tax benefits and certain amounts of temporary differences. The amendments in this standard are effective for annual periods beginning after December 15, 2024. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements. ASU 2024-03 "Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) Disaggregation of Income Statement Expenses." November 2024 The standard provides guidance to enhance disclosures related to the disaggregation of income statement expenses. The standard requires, in the notes to the financial statements, disclosure of specified information about certain costs and expenses which includes purchases of inventory, employee compensation, depreciation, and intangible asset amortization included in each relevant expense caption. The standard also requires amounts that are already required to be disclosed under U.S. GAAP in the same disclosure as the other disaggregation requirements, disclosure of a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, and disclosure of the total amount of selling expenses and, in annual reporting periods, an entity's definition of selling expenses. The amendments in this standard are effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. NA We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements.

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs [Table Text Block]	The following tables summarize our total pre-tax restructuring expenses recorded in fiscal 2025 related to the Restructuring Plan: Three Months Ended December 31, Nine Months Ended December 31, Restructuring Plan Severance and other compensation related costs $ — $ 23,285 Lease and other contract termination and other costs 2,231 6,192 Product rationalization (1) — 2,382 Accelerated depreciation and amortization — 1,250 Total Restructuring Expense $ 2,231 $ 33,109 (1) Recorded in Cost of revenues on the Consolidated Statements of Income.
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]	The following table summarizes our restructuring liability balances: Restructuring Plan Balance at March 31, 2024 $ 678 Fiscal 2025 Charges 29,477 Payments (12,440) Balance at December 31, 2024 $ 17,715

Business Acquisitions and Div_2

Business Acquisitions and Divestitures (Tables)	9 Months Ended
	Dec. 31, 2024
Business Acquisitions and Divestitures [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The table below summarizes the allocation of the purchase price to the net assets acquired from BD based on fair values at the acquisition date. September 30, 2023 Adjustments (2) Final Inventory 27,006 4,821 31,827 Property, plant, and equipment 6,755 1,109 7,864 Lease right-of-use assets, net — 1,737 1,737 Intangible assets (1) 303,598 (598) 303,000 Goodwill 202,399 (5,332) 197,067 Total assets acquired 539,758 1,737 541,495 Lease obligations — 1,737 1,737 Total liabilities assumed — 1,737 1,737 Net assets acquired $ 539,758 $ — $ 539,758 (1) Includes estimated fair values of $238,000 for Customer relationships ( 13 years estimated useful life), $50,000 for Patents and technology ( 13 years estimated useful life), and $15,000 for Trademarks and trade names ( 15 years estimated useful life) as of the acquisition date. (2)

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations	The following table summarizes the major classes of assets and liabilities of the Dental business segment that were classified as held for sale in the Consolidated Balance Sheets as of March 31, 2024: March 31, Assets Assets held-for-sale: Accounts receivable, net $ 48,590 Inventories, net 89,345 Property, plant, and equipment, net 73,395 Lease right-of-use assets, net 22,822 Intangibles, net 770,731 Prepaid expenses and other assets 2,953 Loss accrued on classification as held for sale (202,932) Total assets held-for-sale $ 804,904 Liabilities Liabilities held-for-sale: Accounts payable $ 10,580 Accrued income taxes 433 Accrued payroll and other related liabilities 13,683 Lease obligations 23,722 Accrued expenses and other 15,594 Total liabilities held-for-sale $ 64,012 The following table summarizes the major line items constituting pre-tax income of discontinued operations associated with the Dental segment for the three and nine months ending December 31, 2024 and 2023: Three Months Ended December 31, 2024 Nine Months Ended December 31, 2024 2023 2024 2023 Revenues: Product $ — $ 97,921 $ 63,936 $ 303,233 Cost of revenues: Product — 55,354 35,146 168,908 Gross profit: — 42,567 28,790 134,325 Operating expenses: Selling, general, and administrative — 52,223 13,466 156,972 Research and development — 658 369 2,242 (Loss) income from operations (1) — (10,314) 14,955 (24,889) Non-operating expenses (income), net — (1) 1 (11) Pre-tax loss on sale (97) — (8,210) — (Loss) income before income tax expense (97) (10,313) 6,744 (24,878) Income tax (benefit) expense (21) (2,655) 1,441 (5,978) (Loss) income from discontinued operations, net of income tax (76) (7,658) 5,303 (18,900) (1) Income from operations for the nine month period ended December 31, 2024 includes two months of operating results prior to the transaction close on May 31, 2024 and excludes depreciation and amortization of property, plant, equipment, and intangible assets subsequent to the held for sale classification as of March 2, 2024. The effective income tax rates for the three month periods ending December 31, 2024 and 2023 from discontinued operations were 21.6% and 25.7%, respectively. The effective income tax rates for the nine month periods ending December 31, 2024 and 2023 from discontinued operations were 21.4% and 24.0%, respectively. Significant non-cash operating items and capital expenditures related to discontinued operations are reflected in the statement of cash flows as follows: Nine Months Ended December 31, 2024 2023 Operating activities of discontinued operations: Depreciation, depletion, and amortization $ — $ 90,847 Investing activities of discontinued operations: Purchases of property, plant, equipment, and intangibles, net $ (433) $ (6,722)

Inventories, Net Inventories, N

Inventories, Net Inventories, Net (Tables)	9 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	December 31, March 31, Raw materials $ 229,468 $ 245,942 Work in process 94,262 98,304 Finished goods 367,347 374,182 Reserve for excess and obsolete inventory (41,519) (43,893) Inventories, net $ 649,558 $ 674,535

Property, Plant and Equipment P

Property, Plant and Equipment Property, Plant and Equipment (Tables)	9 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 105,182 $ 90,134 Buildings and leasehold improvements 783,562 724,492 Machinery and equipment 1,184,474 1,075,082 Information systems 285,433 256,671 Radioisotope 737,146 692,642 Construction in progress (1) 509,802 500,106 Total property, plant, and equipment 3,605,599 3,339,127 Less: accumulated depreciation and depletion (1,683,866) (1,573,947) Property, plant, and equipment, net $ 1,921,733 $ 1,765,180 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Tables)

Debt Debt (Tables)	9 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Schedule of Debt	Indebtedness was as follows: December 31, March 31, Short-term debt Term loan, current portion $ — $ 41,250 Delayed draw term loan, current portion — 44,688 Private Placement Senior Notes 125,000 — Total short-term debt $ 125,000 $ 85,938 Long-term debt Private Placement Senior Notes $ 542,352 $ 751,433 Revolving Credit Facility 162,014 484,529 Deferred financing costs (15,641) (17,988) Term loan — 3,750 Delayed draw term loan — 548,438 Senior Public Notes 1,350,000 1,350,000 Total long-term debt $ 2,038,725 $ 3,120,162 Total debt $ 2,163,725 $ 3,206,100

Additional Consolidated Balan_2

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables)	9 Months Ended
	Dec. 31, 2024
Notes To Financial Statements [Abstract]
Additional Consolidated Balance Sheets Information	8. Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 65,256 $ 48,152 Accrued vacation/paid time off 18,215 16,140 Accrued bonuses 48,660 61,669 Accrued employee commissions 25,711 35,980 Other postretirement benefit obligations-current portion 994 994 Other employee benefit plans obligations-current portion 1,949 1,896 Total accrued payroll and other related liabilities $ 160,785 $ 164,831 Accrued expenses and other: Deferred revenues $ 80,033 $ 70,460 Service liabilities 97,306 92,590 Self-insured risk reserves-current portion 19,742 13,303 Accrued dealer commissions 34,705 33,277 Accrued warranty 14,732 15,388 Asset retirement obligation-current portion 560 510 Accrued interest 17,726 11,109 Other 69,782 83,107 Total accrued expenses and other $ 334,586 $ 319,744 Other liabilities: Self-insured risk reserves-long-term portion $ 21,647 $ 21,646 Other postretirement benefit obligations-long-term portion 5,372 5,159 Defined benefit pension plans obligations-long-term portion 3,166 2,727 Other employee benefit plans obligations-long-term portion 1,423 1,321 Accrued long-term income taxes 6,527 6,508 Asset retirement obligation-long-term portion 13,369 13,148 Other 21,625 21,037 Total other liabilities $ 73,129 $ 71,546
Schedule of Accrued Liabilities [Table Text Block]	Additional information related to our Consolidated Balance Sheets is as follows: December 31, March 31, Accrued payroll and other related liabilities: Compensation and related items $ 65,256 $ 48,152 Accrued vacation/paid time off 18,215 16,140 Accrued bonuses 48,660 61,669 Accrued employee commissions 25,711 35,980 Other postretirement benefit obligations-current portion 994 994 Other employee benefit plans obligations-current portion 1,949 1,896 Total accrued payroll and other related liabilities $ 160,785 $ 164,831 Accrued expenses and other: Deferred revenues $ 80,033 $ 70,460 Service liabilities 97,306 92,590 Self-insured risk reserves-current portion 19,742 13,303 Accrued dealer commissions 34,705 33,277 Accrued warranty 14,732 15,388 Asset retirement obligation-current portion 560 510 Accrued interest 17,726 11,109 Other 69,782 83,107 Total accrued expenses and other $ 334,586 $ 319,744 Other liabilities: Self-insured risk reserves-long-term portion $ 21,647 $ 21,646 Other postretirement benefit obligations-long-term portion 5,372 5,159 Defined benefit pension plans obligations-long-term portion 3,166 2,727 Other employee benefit plans obligations-long-term portion 1,423 1,321 Accrued long-term income taxes 6,527 6,508 Asset retirement obligation-long-term portion 13,369 13,148 Other 21,625 21,037 Total other liabilities $ 73,129 $ 71,546

Business Segment Information Bu

Business Segment Information Business Segment Information (Tables)	9 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	The following table compares business segment revenues and business segment and Corporate operating income for the three and nine months e nded December 31, 2024 and 2023: Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Revenues: Healthcare $ 976,044 $ 916,227 $ 2,821,495 $ 2,605,157 AST 258,144 234,931 764,684 703,083 Life Sciences 136,382 146,566 392,805 411,074 Total revenues $ 1,370,570 $ 1,297,724 $ 3,978,984 $ 3,719,314 Income (loss) from operations before adjustments: Healthcare $ 246,917 $ 223,898 $ 691,810 $ 626,134 AST 115,758 105,156 343,374 325,529 Life Sciences 58,133 56,738 164,417 156,863 Corporate (100,843) (81,559) (299,720) (260,452) Total income from operations before adjustments $ 319,965 $ 304,233 $ 899,881 $ 848,074 Less: Adjustments Amortization of acquired intangible assets (1) $ 67,243 $ 64,724 $ 202,875 $ 198,662 Acquisition and integration related charges (2) 3,756 6,263 9,215 24,308 Tax restructuring costs (3) 97 643 54 652 Amortization of inventory and property "step up" to fair value (1) 1,345 6,127 4,138 8,666 Restructuring charges (4) 2,231 6 33,109 2 Income from operations $ 245,293 $ 226,470 $ 650,490 $ 615,784 (1) For more information regarding our recent acquisitions and divestitures, refer to Note 3 titled, "Business Acquisitions and Divestitures." (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in tax restructuring. (4) For more information regarding our restructuring efforts, refer to Note 2 titled, "Restructuring ."
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Healthcare: Capital equipment $ 254,804 $ 266,838 $ 719,175 $ 759,842 Consumables 358,233 329,435 1,043,294 915,741 Service 363,007 319,954 1,059,026 929,574 Total Healthcare Revenues $ 976,044 $ 916,227 $ 2,821,495 $ 2,605,157 AST: Capital equipment $ 5,004 $ 5,241 $ 14,897 $ 7,869 Service 253,140 229,690 749,787 695,214 Total AST Revenues $ 258,144 $ 234,931 $ 764,684 $ 703,083 Life Sciences: Capital equipment $ 31,063 $ 44,836 $ 80,551 $ 111,265 Consumables 68,676 60,072 210,619 181,179 Service 36,643 41,658 101,635 118,630 Total Life Sciences Revenues $ 136,382 $ 146,566 $ 392,805 $ 411,074 Total Revenues $ 1,370,570 $ 1,297,724 $ 3,978,984 $ 3,719,314
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Revenues: Ireland $ 24,117 $ 19,601 $ 69,113 $ 60,037 United States 1,002,586 949,957 2,929,004 2,715,397 Other locations 343,867 328,166 980,867 943,880 Total Revenues $ 1,370,570 $ 1,297,724 $ 3,978,984 $ 3,719,314

Shares and Preferred Shares Sha

Shares and Preferred Shares Shares and Preferred Shares (Tables)	9 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended December 31, Nine Months Ended December 31, Denominator (shares in thousands): 2024 2023 2024 2023 Weighted average shares outstanding—basic 98,490 98,802 98,676 98,765 Dilutive effect of share equivalents 452 552 498 568 Weighted average shares outstanding and share equivalents—diluted 98,942 99,354 99,174 99,333
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive: Three Months Ended December 31, Nine Months Ended December 31, (shares in thousands) 2024 2023 2024 2023 Number of share options 794 654 686 649

Share-Based Compensation Share-

Share-Based Compensation Share-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Assumptions Used	The following weighted average assumptions were used for options granted during the first nine months of fiscal 2025 and 2024: Fiscal 2025 Fiscal 2024 Risk-free interest rate 4.21 % 3.59 % Expected life of options 6.1 years 6.0 years Expected dividend yield of stock 0.94 % 1.08 % Expected volatility of stock 28.42 % 27.92 %
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	A summary of share option activity is as follows: Number of Weighted Average Aggregate Outstanding at March 31, 2024 1,869,871 $ 168.22 Granted 217,426 250.76 Exercised (190,441) 107.21 Forfeited (9,976) 237.01 Expired (512) 250.06 Outstanding at December 31, 2024 1,886,368 $ 183.51 5.9 years $ 67,166 Exercisable at December 31, 2024 1,334,958 $ 161.48 4.9 years $ 67,166
Share-based Compensation Arrangements by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest	A summary of the non-vested restricted share and share unit activity is presented below: Number of Number of Restricted Share Units Weighted Average Non-vested at March 31, 2024 463,381 28,348 $ 200.04 Granted 160,789 16,865 228.97 Vested (131,250) (12,248) 186.21 Forfeited (38,911) (1,792) 207.88 Non-vested at December 31, 2024 454,009 31,173 $ 214.16

Financial and Other Guarantees

Financial and Other Guarantees Financial and Other Gurantees (Tables)	9 Months Ended
	Dec. 31, 2024
Product Warranties Disclosures [Abstract]
Schedule of Product Warranty Liability	Changes in our warranty liability during the first nine months of fiscal 2025 were as follows: Warranties Balance at March 31, 2024 $ 15,388 Warranties issued during the period 12,732 Settlements made during the period (13,388) Balance at December 31, 2024 $ 14,732

Derivatives and Hedging Derivat

Derivatives and Hedging Derivatives and Hedging (Tables)	9 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	Asset Derivatives Liability Derivatives Fair Value at Fair Value at Fair Value at Fair Value at Balance sheet location December 31, 2024 March 31, 2024 December 31, 2024 March 31, 2024 Prepaid & other $ 489 $ 208 $ — $ — Accrued expenses and other $ — $ — $ 772 $ 1,014
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income: Location of gain (loss) Amount of gain (loss) recognized in income Three Months Ended December 31, Nine Months Ended December 31, 2024 2023 2024 2023 Foreign currency forward contracts Selling, general and administrative $ (2,642) $ (292) $ 259 $ 1,226 Commodity swap contracts Cost of revenues $ (342) $ (316) $ (193) $ (1,708)

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Tables)	9 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Option, Disclosures	The following table shows the fair value of our financial assets and liabilities at December 31, 2024 and March 31, 2024: Fair Value Measurements Carrying Value Quoted Prices Significant Other Significant Level 1 Level 2 Level 3 December 31, March 31, December 31, March 31, December 31, March 31, December 31, March 31, Assets: Cash and cash equivalents $ 155,178 $ 207,020 $ 155,178 $ 207,020 $ — $ — $ — $ — Forward and swap contracts (1) 489 208 — — 489 208 — — Equity investments (2) 1,240 4,767 1,240 4,767 — — — — Other investments 2,803 2,902 2,803 2,902 — — — — Liabilities: Forward and swap contracts (1) $ 772 $ 1,014 $ — $ — $ 772 $ 1,014 $ — $ — Deferred compensation plans (2) 1,272 1,186 1,272 1,186 — — — — Debt (3) 2,163,725 3,206,100 — — 1,848,204 2,895,784 — — Contingent consideration obligations (4) 11,625 11,000 — — — — 11,625 11,000 (1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). Changes in the fair value of these investments are recorded in the "Interest and miscellaneous income" line of the Consolidated Statement of Income. During the first three and nine months of fiscal 2025, we recorded gains of $774 and $878, respectively, related to these investments. During the first three and nine months of fiscal 2024, we recorded gains of $881 and $1,019, respectively, related to these investments. We also held other equity investments in which we recorded a loss during the second quarter of fiscal 2025 in the "Gain on sale of business and equity investment, net" line of the Consolidated Statement of Income. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. The fair values of our Senior Public Notes are estimated using quoted market prices for the Senior Public Notes. (4) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at December 31, 2024 are summarized as follows: Contingent Consideration Balance at March 31, 2024 $ 11,000 Additions 671 Payments (60) Currency translation adjustments 14 Balance at December 31, 2024 $ 11,625

Reclassifications out of Accu_2

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Dec. 31, 2024
Reclassifications out of AOCI [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three and nine months ended December 31, 2024 and 2023 were as follows: Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Loss Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ (845) $ (724) $ (164,991) $ (327,933) $ (165,836) $ (328,657) Other Comprehensive Income (Loss) before reclassifications 118 147 (208,418) (72,569) (208,300) (72,422) Amounts reclassified from Accumulated Other Comprehensive Income (Loss) (76) (226) (38) 27,055 (114) 26,829 Net current-period Other Comprehensive Income (Loss) 42 (79) (208,456) (45,514) (208,414) (45,593) Balance at December 31, 2024 $ (803) $ (803) $ (373,447) $ (373,447) $ (374,250) $ (374,250) (1) The amortization (gain) of defined benefit pension items is reported in the Interest and miscellaneous (income) expense line of our Consolidated Statements of Income. (2) The amounts previously recognized in currency translation adjustments related to our Dental business were reclassified when realized and included in the calculation of the loss on sale, net of previous accrued losses, within (Loss) income from discontinued operations, net of tax, for the nine month period ended December 31, 2024. Defined Benefit Plans (1) Currency Translation (2) Total Accumulated Other Comprehensive Loss Three Months Nine Months Three Months Nine Months Three Months Nine Months Beginning Balance $ 129 $ 12 $ (386,864) $ (320,722) $ (386,735) $ (320,710) Other Comprehensive Income (Loss) before reclassifications 408 1,160 134,048 67,906 134,456 69,066 Amounts reclassified from Accumulated Other Comprehensive Loss (350) (985) — — (350) (985) Net current-period Other Comprehensive Income (Loss) 58 175 134,048 67,906 134,106 68,081 Balance at December 31, 2023 $ 187 $ 187 $ (252,816) $ (252,816) $ (252,629) $ (252,629) 1)

Nature of Operations and Summ_4

Nature of Operations and Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Product Information [Line Items]
Deferred Revenue, Revenue Recognized	$ 57,650	$ 70,181
Revenue, Remaining Performance Obligation, Amount	$ 1,675,500
Expected recognition within the next year [Member]
Product Information [Line Items]
Revenue, Remaining Performance Obligation, Percentage	53%
Expected recognition beyond the next year [Member] [Member]
Product Information [Line Items]
Revenue, Remaining Performance Obligation, Percentage	36%
Discontinued Operations, Dental Segment
Product Information [Line Items]
Potential Earnout on Divestiture of Business	$ 12,500
Discontinued Operations, Held-for-Sale | Discontinued Operations, Dental Segment
Product Information [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 787,500

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($) unit	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Number of Positions Eliminated | unit			300
Restructuring Charges	$ 2,231	$ 6	$ 33,109	$ 2
Fiscal 2024/2025 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	2,231		33,109		$ 77,499
Restructuring and Related Cost, Expected Cost Remaining	$ 20,000		$ 20,000		20,000
Fiscal 2024/2025 Restructuring Plan | Cost of Sales
Restructuring Cost and Reserve [Line Items]
Restructuring Charges					$ 20,702

Restructuring - Restructuring E

Restructuring - Restructuring Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 2,231	$ 6	$ 33,109	$ 2
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance			678
Restructuring Reserve, Accrual Adjustment			29,477
Restructuring Reserve, Period Increase (Decrease)			(12,440)
Restructuring Reserve, Ending Balance	17,715		17,715		$ 17,715
Fiscal 2024/2025 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	2,231		33,109		77,499
Employee Severance | Fiscal 2024/2025 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	0		23,285
Contract Termination | Fiscal 2024/2025 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	2,231		6,192
Reduced Depreciation | Fiscal 2024/2025 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	0		1,250
Product Rationalization | Fiscal 2024/2025 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 0		$ 2,382
Cost of Sales | Fiscal 2024/2025 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring Charges					$ 20,702

Business Acquisitions and Div_3

Business Acquisitions and Divestitures - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired			$ 53,659	$ 539,758
Asset Acquisition, Price of Acquisition Net of Tax Benefit, Expected				60,000
Business Combination, Acquisition Related Costs	$ 3,756	$ 6,263	9,215	24,308
Revenues	1,370,570	$ 1,297,724	3,978,984	3,719,314
Discontinued Operations, Dental Segment
Business Acquisition [Line Items]
Potential Earnout on Divestiture of Business			12,500
CECS
Business Acquisition [Line Items]
Proceeds from Divestiture of Businesses			41,894
Pre-tax gain or loss on sale of business			19,263
Revenues					$ 35,000
Discontinued Operations, Held-for-Sale | Discontinued Operations, Dental Segment
Business Acquisition [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 787,500		787,500
BD Acquisition
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 539,758
Other FY 25 Acquisition
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired			$ 53,659

Business Acquisitions and Div_4

Business Acquisitions and Divestitures - Allocation of the Purchase Price (Details) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2024	Mar. 31, 2024	Sep. 30, 2023
Business Acquisition [Line Items]
Lease right-of-use assets, net		$ 153,879	$ 173,201
Goodwill		4,044,198	$ 4,070,712
BD Acquisition
Business Acquisition [Line Items]
Inventory		31,827		$ 27,006
Property, plant, and equipment		7,864		6,755
Lease right-of-use assets, net		1,737		0
Intangible assets		303,000		303,598
Goodwill		197,067		202,399
Total assets acquired		541,495		539,758
Lease obligations		1,737		0
Total liabilities assumed		1,737		0
Net assets acquired		539,758		$ 539,758
Adjustments
Inventory	$ 4,821
Property, plant, and equipment	1,109
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Leases Right of Use Asset	1,737
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles	(598)
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill	(5,332)
Total assets acquired	1,737
Lease obligations	1,737
Total liabilities assumed	1,737
Net assets acquired	$ 0
BD Acquisition | Customer Relationships [Member]
Business Acquisition [Line Items]
Intangible assets		$ 238,000
BD Acquisition | Customer-Related Intangible Assets
Adjustments
Finite-Lived Intangible Asset, Useful Life		13 years
BD Acquisition | Patented Technology
Business Acquisition [Line Items]
Intangible assets		$ 50,000
Adjustments
Finite-Lived Intangible Asset, Useful Life		13 years
BD Acquisition | Trademarks and Trade Names
Business Acquisition [Line Items]
Intangible assets		$ 15,000
Adjustments
Finite-Lived Intangible Asset, Useful Life		15 years

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Effective Income Tax Rate Reconciliation, Disposition of Business, Percent	21.60%	25.70%	21.40%	24%
Discontinued Operations, Dental Segment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Potential Earnout on Divestiture of Business			$ 12,500
Discontinued Operations, Held-for-Sale | Discontinued Operations, Dental Segment
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal Group, Including Discontinued Operation, Consideration	$ 787,500		$ 787,500

Discontinued Operations - Summa

Discontinued Operations - Summary Assets and Liabilities Classified as Held for Sale (Details) - Discontinued Operations, Held-for-Sale - Discontinued Operations, Dental Segment $ in Thousands	Mar. 31, 2024 USD ($)
Assets held for sale:
Accounts receivable, net	$ 48,590
Inventories, net	89,345
Property, plant, and equipment, net	73,395
Lease right-of-use assets, net	22,822
Intangibles, net	770,731
Prepaid expenses and other assets	2,953
Loss accrued on classification as held for sale	(202,932)
Total assets held-for-sale	804,904
Liabilities held for sale:
Accounts payable	10,580
Accrued income taxes	433
Accrued payroll and other related liabilities	13,683
Lease obligations	23,722
Accrued expenses and other	15,594
Total liabilities held-for-sale	$ 64,012

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Pre-Tax Income of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Cost of revenues:
Loss adjustment on sale	$ 97		$ (8,210)
Pre-tax loss adjustment on sale		$ 0		$ 0
(Loss) income from discontinued operations, net of income tax	(76)	(7,658)	5,303	(18,900)
Discontinued Operations, Held-for-Sale | Discontinued Operations, Dental Segment
Revenues:
Product	0	97,921	63,936	303,233
Cost of revenues:
Product	0	55,354	35,146	168,908
Gross profit:	0	42,567	28,790	134,325
Selling, general, and administrative	0	52,223	13,466	156,972
Research and development	0	658	369	2,242
(Loss) income from operations (1)	0	(10,314)	14,955	(24,889)
Non-operating expenses (income), net	0	(1)	(1)	(11)
(Loss) income before income tax expense	(97)	(10,313)	6,744	(24,878)
Income tax (benefit) expense	(21)	(2,655)	1,441	(5,978)
(Loss) income from discontinued operations, net of income tax	$ (76)	$ (7,658)	$ 5,303	$ (18,900)

Discontinued Operations - Sum_3

Discontinued Operations - Summary of Significant Non-Cash Operating Items and Capital Expenditures Related to Discontinued Operations (Details) - Discontinued Operations, Held-for-Sale - Discontinued Operations, Dental Segment - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation, depletion, and amortization	$ 0	$ 90,847
Purchases of property, plant, equipment, and intangibles, net	$ (433)	$ (6,722)

Inventories, Net Inventories,_2

Inventories, Net Inventories, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Raw materials	$ 229,468	$ 245,942
Work in process	94,262	98,304
Finished goods	367,347	374,182
Reserve for excess and obsolete inventory	(41,519)	(43,893)
Inventories, net	$ 649,558	$ 674,535

Property, Plant and Equipment_2

Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($) $ in Thousands		9 Months Ended
		Dec. 31, 2024	Mar. 31, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment		Information related to the major categories of our depreciable assets is as follows: December 31, March 31, Land and land improvements (1) $ 105,182 $ 90,134 Buildings and leasehold improvements 783,562 724,492 Machinery and equipment 1,184,474 1,075,082 Information systems 285,433 256,671 Radioisotope 737,146 692,642 Construction in progress (1) 509,802 500,106 Total property, plant, and equipment 3,605,599 3,339,127 Less: accumulated depreciation and depletion (1,683,866) (1,573,947) Property, plant, and equipment, net $ 1,921,733 $ 1,765,180 (1) Land is not depreciated. Construction in progress is not depreciated until placed in service.
Property, Plant and Equipment [Line Items]
Land and land improvements	[1]	$ 105,182	$ 90,134
Buildings and leasehold improvements		783,562	724,492
Machinery and equipment		1,184,474	1,075,082
Capitalized Computer Hardware/Software, Gross		285,433	256,671
Radioisotope		737,146	692,642
Construction in progress	[1]	509,802	500,106
Total property, plant, and equipment		3,605,599	3,339,127
Less: accumulated depreciation and depletion		(1,683,866)	(1,573,947)
Property, plant, and equipment, net		$ 1,921,733	$ 1,765,180
[1] Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt Debt (Details)

Debt Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Oct. 07, 2024	Mar. 31, 2024
Debt Instrument [Line Items]
Term loan, current portion	$ 0		$ 41,250
Delayed draw term loan, current portion	0		44,688
Short-term Debt	125,000		85,938
Credit Agreement	162,014		484,529
Deferred financing costs	(15,641)		(17,988)
Term Loan	0		3,750
Delayed Draw Term Loan	0		548,438
Total long term debt	2,038,725		3,120,162
Debt, Long-term and Short-term, Combined Amount	2,163,725		3,206,100
Private Placement
Debt Instrument [Line Items]
Senior Notes, Noncurrent	542,352		751,433
Senior Notes
Debt Instrument [Line Items]
Senior Notes, Noncurrent	1,350,000		1,350,000
Line of Credit | Revolving Credit Facility
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,100,000
Line of Credit Facility, Covenant, Maximum Alternative Currency Advances		$ 625,000
Private Placement
Debt Instrument [Line Items]
Senior Notes, Current	$ 125,000		$ 0

Additional Consolidated Balan_3

Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Mar. 31, 2024
Accrued payroll and other related liabilities:
Compensation and related items	$ 65,256	$ 48,152
Accrued vacation/paid time off	18,215	16,140
Accrued bonuses	48,660	61,669
Accrued employee commissions	25,711	35,980
Other postretirement benefit obligations-current portion	994	994
Other employee benefit plans obligations-current portion	1,949	1,896
Employee-related Liabilities, Current	160,785	164,831
Accrued expenses and other:
Deferred revenues	80,033	70,460
Service liabilities	97,306	92,590
Self-insured risk reserves-current portion	19,742	13,303
Accrued dealer commissions	34,705	33,277
Accrued warranty	14,732	15,388
Asset retirement obligation-current portion	560	510
Accrued interest	17,726	11,109
Other	69,782	83,107
Accrued Liabilities, Current	334,586	319,744
Other liabilities:
Self-insured risk reserves-long-term portion	21,647	21,646
Other postretirement benefit obligations-long-term portion	5,372	5,159
Defined benefit pension plans obligations-long-term portion	3,166	2,727
Other employee benefit plans obligations-long-term portion	1,423	1,321
Accrued long-term income taxes	6,527	6,508
Asset retirement obligation-long-term portion	13,369	13,148
Long-term liabilities, other	21,625	21,037
Other Liabilities, Noncurrent	$ 73,129	$ 71,546

Income Tax Expense Income Tax E

Income Tax Expense Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Effective Income Tax Rate, Continuing Operations	24.20%	21.60%	22.40%	21.90%
Uncertain Tax Liability Resulting From IRS Notice	$ 50,000		$ 50,000
Income Tax Examination, Estimate of Possible Loss			$ 12,000

Contingencies (Details)

Contingencies (Details)	Dec. 31, 2024 plaintiff
Commitments and Contingencies Disclosure [Abstract]
Number of plaintiffs	250

Business Segment Information -

Business Segment Information - Narrative (Details)	9 Months Ended
	Dec. 31, 2024 segment
Segment Reporting [Abstract]
Number of reportable segments	3

Business Segment Information _2

Business Segment Information Business Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Revenues	$ 1,370,570	$ 1,297,724	$ 3,978,984	$ 3,719,314
Segment operating income	245,293	226,470	650,490	615,784
Amortization of acquired intangible assets	67,243	64,724	202,875	198,662
Business Combination, Acquisition Related Costs	3,756	6,263	9,215	24,308
Impact of TCJA	97	643	54	652
Amortization of inventory and property step-up to fair value	1,345	6,127	4,138	8,666
Restructuring Charges	2,231	6	33,109	2
IRELAND
Segment Reporting Information [Line Items]
Revenues	24,117	19,601	69,113	60,037
UNITED STATES
Segment Reporting Information [Line Items]
Revenues	1,002,586	949,957	2,929,004	2,715,397
Other foreign locations
Segment Reporting Information [Line Items]
Revenues	343,867	328,166	980,867	943,880
Healthcare [Member] [Member]
Segment Reporting Information [Line Items]
Revenues	976,044	916,227	2,821,495	2,605,157
Segment operating income	246,917	223,898	691,810	626,134
Healthcare [Member] [Member] | Capital equipment revenues [Member]
Segment Reporting Information [Line Items]
Revenues	254,804	266,838	719,175	759,842
Healthcare [Member] [Member] | Consumable revenues [Member]
Segment Reporting Information [Line Items]
Revenues	358,233	329,435	1,043,294	915,741
Healthcare [Member] [Member] | Sales Revenue, Services, Net [Member]
Segment Reporting Information [Line Items]
Revenues	363,007	319,954	1,059,026	929,574
Applied Sterilization Technologies
Segment Reporting Information [Line Items]
Revenues	258,144	234,931	764,684	703,083
Segment operating income	115,758	105,156	343,374	325,529
Applied Sterilization Technologies | Capital equipment revenues [Member]
Segment Reporting Information [Line Items]
Revenues	5,004	5,241	14,897	7,869
Applied Sterilization Technologies | Sales Revenue, Services, Net [Member]
Segment Reporting Information [Line Items]
Revenues	253,140	229,690	749,787	695,214
Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues	136,382	146,566	392,805	411,074
Segment operating income	58,133	56,738	164,417	156,863
Life Science Member [Member] | Capital equipment revenues [Member]
Segment Reporting Information [Line Items]
Revenues	31,063	44,836	80,551	111,265
Life Science Member [Member] | Consumable revenues [Member]
Segment Reporting Information [Line Items]
Revenues	68,676	60,072	210,619	181,179
Life Science Member [Member] | Sales Revenue, Services, Net [Member]
Segment Reporting Information [Line Items]
Revenues	36,643	41,658	101,635	118,630
Corporate
Segment Reporting Information [Line Items]
Segment operating income	(100,843)	(81,559)	(299,720)	(260,452)
Segment operating income
Segment Reporting Information [Line Items]
Segment operating income	$ 319,965	$ 304,233	$ 899,881	$ 848,074

Shares and Preferred Shares Ord

Shares and Preferred Shares Ordinary Shares (Details)	3 Months Ended		9 Months Ended
	Dec. 31, 2024 $ / shares shares	Dec. 31, 2023 shares	Dec. 31, 2024 $ / shares shares	Dec. 31, 2023 shares	Dec. 31, 2024 EUR (€) shares
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average shares outstanding - basic	98,490,000	98,802,000	98,676,000	98,765,000
Dilutive effect of share equivalents	452,000	552,000	498,000	568,000
Weighted average shares outstanding and share equivalents - diluted	98,942,000	99,354,000	99,174,000	99,333,000
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Preferred Stock, Shares Authorized					50,000,000
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.001		$ 0.001
Deferred Ordinary Shares					25,000
Employee share option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of share options that are antidilutive	794,000	654,000	686,000	649,000
Euro Member Countries, Euro
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Par Value (Euros) of Deferred Ordinary Shares | €					€ 1

Repurchases of Shares (Details)

Repurchases of Shares (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	May 03, 2023
Equity [Abstract]
Share repurchase program, number of shares authorized			$ 500,000
Share Repurchase Program, Remaining Authorized, Amount	$ 300,000
Shares repurchased during period, number	907,158
Ordinary Stock Repurchases Not Including Shares Withheld for Taxes	$ 200,000
Shares obtained in connection with share based compensation award programs	87,436	69,276
Payments for shares obtained in connection with share based compensation programs	$ 11,040	$ 11,440

Share-Based Compensation Shar_2

Share-Based Compensation Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	2,027,503
Weighted-average assumptions used for options granted:
Risk-free interest rate	4.21%	3.59%
Expected life of options	6 years 1 month 6 days	6 years
Exptected dividend yield of stock	0.94%	1.08%
Expected volatility of stock	28.42%	27.92%
Estimated forfeiture rate	2.07%	2.22%
Summary of share option activity:
Outstanding at the beginning of the period	1,869,871
Granted	217,426
Exercised	(190,441)
Forfeited	(9,976)
Canceled	(512)
Outstanding at the end of the period	1,886,368
Exercisable at the end of the period	1,334,958
Weighted average exercise price:
Outstanding at the beginning of the period	$ 168.22
Granted	250.76
Exercised	107.21
Forfeited	237.01
Canceled	250.06
Outstanding at the end of the period	183.51
Exercisable at the end of the period	$ 161.48
Average Remaining Contractual Term, Outstanding at the end of the period	5 years 10 months 24 days
Aggregate Intrinsic Value, Outstanding at the end of the period	$ 67,166
Average Remaining Contractual Term, Exercisable at the end of the period	4 years 10 months 24 days
Aggregate Intrinsic Value, Exercisable at the end of the period	$ 67,166
Non-vested stock options outstanding expected to vest	541,677
Ordinary shares, closing price	$ 205.56
Total intrinsic value of stock options exercised	$ 24,647	$ 8,350
Net cash proceeds from the exercise of stock options	$ 19,380	$ 3,526
Weighted average grant date fair value of stock option grants, per share	$ 67.81	$ 54.60
Summary of non-vested restricted share activity:
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 60,400
Weighted Average Period For Total Compensation Expense Not Yet Recognized	1 year 8 months 12 days
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	463,381
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 200.04
Number of Restricted Shares, Granted	160,789
Weighted-Average Grant Date Fair Value, Granted	$ 228.97
Number of Restricted Shares, Vested	(131,250)
Weighted-Average Grant Date Fair Value, Vested	$ 186.21
Number of Restricted Shares, Canceled	(38,911)
Weighted-Average Grant Date Fair Value, Canceled	$ 207.88
Number of Restricted Shares, Non-vested at End of Period	454,009
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 214.16
Fair Value, Share-based Payment Awards, Other than Options	$ 26,891
Restricted Stock Units (RSUs)
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	28,348
Number of Restricted Shares, Granted	16,865
Number of Restricted Shares, Vested	(12,248)
Number of Restricted Shares, Canceled	(1,792)
Number of Restricted Shares, Non-vested at End of Period	31,173

Financial and Other Guarantee_2

Financial and Other Guarantees Financial and Other Guarantees (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2024 USD ($)
Product Warranty Liability [Line Items]
Balance, Beginning of the Period	$ 15,388
Warranties issued during the period	12,732
Settlement made during the period	(13,388)
Balance, End of the Period	$ 14,732

Derivatives and Hedging Fair Va

Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) $ in Thousands, € in Millions, £ in Millions, $ in Millions, $ in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2024 USD ($) lb	Dec. 31, 2023 USD ($)	Dec. 31, 2024 GBP (£)	Dec. 31, 2024 CAD ($)	Dec. 31, 2024 MXN ($)	Dec. 31, 2024 AUD ($)	Dec. 31, 2024 EUR (€)	Dec. 31, 2024 USD ($)	Mar. 31, 2024 USD ($)
Prepaid & Other
Derivative [Line Items]
Asset derivatives										$ 489	$ 208
Liability derivatives										0	0
Accrued expenses and other
Derivative [Line Items]
Asset derivatives										0	0
Liability derivatives										$ 772	$ 1,014
Foreign currency forward contracts | Selling, general, and administrative expense
Derivative [Line Items]
Amount of gain (loss) recognized in income	$ (2,642)	$ (292)	$ 259	$ 1,226
Commodity swap contracts
Derivative [Line Items]
Derivative, notional amount, weight | lb			197,300
Commodity swap contracts | Cost of Sales
Derivative [Line Items]
Amount of gain (loss) recognized in income	$ (342)	$ (316)	$ (193)	$ (1,708)
British pounds sterling | Foreign currency forward contracts
Derivative [Line Items]
Liability derivatives | £					£ 40
Australia, Dollars | Foreign currency forward contracts
Derivative [Line Items]
Derivative Asset, Notional Amount								$ 15
Canadian dollar | Foreign currency forward contracts
Derivative [Line Items]
Liability derivatives						$ 14
euro | Foreign currency forward contracts
Derivative [Line Items]
Derivative Asset, Notional Amount | €									€ 8.4
Mexico, Pesos | Foreign currency forward contracts
Derivative [Line Items]
Liability derivatives							$ 49

Derivatives and Hedging Gain (L

Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Foreign currency forward contracts | Selling, general, and administrative expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (2,642)	$ (292)	$ 259	$ 1,226
Commodity swap contracts | Cost of revenues
Derivative Instruments, Gain (Loss) [Line Items]
Amount of gain (loss) recognized in income	$ (342)	$ (316)	$ (193)	$ (1,708)

Fair Value Measurements Fair _2

Fair Value Measurements Fair Value Hierarchy (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt and Equity Securities, Gain (Loss)		$ (774)	$ (881)	$ (878)	$ (1,019)
Liabilities:
Contingent consideration obligations		11,625		11,625		$ 11,000
Level 1
Assets:
Cash and cash equivalents		155,178		155,178		207,020
Forward and swap contracts		0		0		0
Equity Securities, FV-NI	[1]	1,240		1,240		4,767
Investments		2,803		2,803		2,902
Liabilities:
Foreign Currency Contracts, Liability, Fair Value Disclosure		0		0		0
Deferred compensation plans	[1]	1,272		1,272		1,186
Long term debt	[2]	0		0		0
Contingent consideration obligations		0		0		0
Level 2
Assets:
Cash and cash equivalents		0		0		0
Forward and swap contracts	[3]	489		489		208
Equity Securities, FV-NI		0		0		0
Investments		0		0		0
Liabilities:
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]	772		772		1,014
Deferred compensation plans		0		0		0
Long term debt	[2]	1,848,204		1,848,204		2,895,784
Contingent consideration obligations		0		0		0
Level 3
Assets:
Cash and cash equivalents		0		0		0
Forward and swap contracts		0		0		0
Equity Securities, FV-NI		0		0		0
Investments		0		0		0
Liabilities:
Foreign Currency Contracts, Liability, Fair Value Disclosure		0		0		0
Deferred compensation plans		0		0		0
Debt Instrument, Fair Value Disclosure	[2]	0		0		0
Contingent consideration obligations	[4]	11,625		11,625		11,000
Reported Value Measurement [Member]
Assets:
Cash and cash equivalents		155,178		155,178		207,020
Forward and swap contracts	[3]	489		489		208
Equity Securities, FV-NI	[1]	1,240		1,240		4,767
Investments		2,803		2,803		2,902
Liabilities:
Foreign Currency Contracts, Liability, Fair Value Disclosure	[3]	772		772		1,014
Deferred compensation plans	[1]	1,272		1,272		1,186
Long term debt	[2]	2,163,725		2,163,725		3,206,100
Contingent consideration obligations		$ 11,625		$ 11,625		$ 11,000
[1] We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). Changes in the fair value of these investments are recorded in the "Interest and miscellaneous income" line of the Consolidated Statement of Income. During the first three and nine months of fiscal 2025, we recorded gains of $774 and $878, respectively, related to these investments. During the first three and nine months of fiscal 2024, we recorded gains of $881 and $1,019, respectively, related to these investments. We also held other equity investments in which we recorded a loss during the second quarter of fiscal 2025 in the "Gain on sale of business and equity investment, net" line of the Consolidated Statement of Income. We estimate the fair value of our debt using discounted cash flow analyses, based on estimated current incremental borrowing rates for similar types of borrowing arrangement s. The fair values of our Senior Public Notes are estimated using quoted market prices for the Senior Public Notes. The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.

Fair Value Measurements Availab

Fair Value Measurements Available-for-sale securities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2023
Debt Securities, Available-for-Sale [Abstract]
Equity Securities, FV-NI, Gain (Loss)	$ 774	$ 881	$ 878	$ 1,019

Fair Value Measurements Conting

Fair Value Measurements Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2024	Mar. 31, 2024
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Contingent consideration	$ 11,625	$ 11,000
Additions
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration	671
Payments
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration	(60)
Foreign currency translation adjustment
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in contingent consideration	$ 14

Reclassifications out of Accu_3

Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands		3 Months Ended				9 Months Ended
		Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2024		Dec. 31, 2023		Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		$ (114)		$ (350)	[1]	$ 26,829		$ (985)
Other comprehensive income		(208,414)		134,106		(45,593)		68,081
Accumulated Other Comprehensive Income (Loss), Net of Tax		(374,250)		(252,629)		(374,250)		(252,629)		$ (165,836)	$ (328,657)	$ (386,735)	$ (320,710)
Other Comprehensive Income (Loss), Net of Tax		(208,300)		134,456		(72,422)		69,066
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax		(803)		187		(803)		187		(845)	(724)	129	12
Other Comprehensive Income (Loss), Net of Tax		118		408		147		1,160
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	[2]	(76)		(350)		(226)		(985)
Other comprehensive income		42		58		(79)		175
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax		(38)	[1]	0		27,055	[1]	0	[1]
Other comprehensive income		(208,456)		134,048		(45,514)		67,906
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax		(373,447)		(252,816)		(373,447)		(252,816)		$ (164,991)	$ (327,933)	$ (386,864)	$ (320,722)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax		$ (208,418)		$ 134,048		$ (72,569)		$ 67,906
[1]The amounts previously recognized in currency translation adjustments related to our Dental business were reclassified when realized and included in the calculation of the loss on sale, net of previous accrued losses, within (Loss) income from discontinued operations, net of tax, for the nine month period ended December 31, 2024.[2]The amortization (gain) of defined benefit pension items is reported in the Interest and miscellaneous (income) expense line of our Consolidated Statements of Income.